Cargando…
Sustained Activation of Endothelial YAP1 Causes Epithelioid Hemangioendothelioma
Autores principales: | Jung, Roy, Janardhan, Harish P., Dresser, Karen, Cotton, Jennifer L., Hutchinson, Lloyd, Mao, Junhao, Trivedi, Chinmay M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216595/ https://www.ncbi.nlm.nih.gov/pubmed/34078092 http://dx.doi.org/10.1161/ATVBAHA.121.316300 |
Ejemplares similares
-
Pathological MAPK activation–mediated lymphatic basement membrane disruption causes lymphangiectasia that is treatable with ravoxertinib
por: Janardhan, Harish P., et al.
Publicado: (2022) -
KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K–MAPK1 inhibition
por: Janardhan, Harish Palleti, et al.
Publicado: (2020) -
Hepatic YAP1-TFE3 Rearranged Epithelioid Hemangioendothelioma
por: Lotfalla, Mira M., et al.
Publicado: (2019) -
Primary Renal Epithelioid Hemangioendothelioma
por: Roy, S., et al.
Publicado: (2012) -
Pleural Epithelioid Hemangioendothelioma
por: Lee, Young Joo, et al.
Publicado: (2008)